Cobimetinib racemate
≥99%
- Product Code: 100153
CAS:
934662-91-6
| Molecular Weight: | 531.3099999999999 g./mol | Molecular Formula: | C₂₁H₂₁F₃IN₃O₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8℃ |
Product Description:
Cobimetinib racemate is primarily used in the field of oncology, particularly in the treatment of certain types of cancer. It functions as a MEK inhibitor, which means it targets and inhibits the MEK enzyme, a component of the MAPK/ERK pathway. This pathway is often dysregulated in cancers, leading to uncontrolled cell growth and proliferation.
One of the key applications of Cobimetinib racemate is in the treatment of metastatic melanoma, especially when used in combination with other targeted therapies like vemurafenib. The combination therapy has shown to be effective in improving progression-free survival and overall response rates in patients with BRAF V600 mutation-positive melanoma.
Additionally, Cobimetinib racemate is being investigated for its potential use in other cancers where the MAPK/ERK pathway plays a critical role. This includes colorectal cancer, non-small cell lung cancer, and thyroid cancer, among others. Clinical trials are ongoing to explore its efficacy and safety in these and other cancer types.
The development and use of Cobimetinib racemate represent a significant advancement in targeted cancer therapy, offering hope for improved outcomes in patients with specific genetic mutations driving their cancer.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.002 | 10-20 days | Ft110,542.35 |
+
-
|
| 0.005 | 10-20 days | Ft165,813.52 |
+
-
|
Cobimetinib racemate
Cobimetinib racemate is primarily used in the field of oncology, particularly in the treatment of certain types of cancer. It functions as a MEK inhibitor, which means it targets and inhibits the MEK enzyme, a component of the MAPK/ERK pathway. This pathway is often dysregulated in cancers, leading to uncontrolled cell growth and proliferation.
One of the key applications of Cobimetinib racemate is in the treatment of metastatic melanoma, especially when used in combination with other targeted therapies like vemurafenib. The combination therapy has shown to be effective in improving progression-free survival and overall response rates in patients with BRAF V600 mutation-positive melanoma.
Additionally, Cobimetinib racemate is being investigated for its potential use in other cancers where the MAPK/ERK pathway plays a critical role. This includes colorectal cancer, non-small cell lung cancer, and thyroid cancer, among others. Clinical trials are ongoing to explore its efficacy and safety in these and other cancer types.
The development and use of Cobimetinib racemate represent a significant advancement in targeted cancer therapy, offering hope for improved outcomes in patients with specific genetic mutations driving their cancer.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
Ft0.00
Ft0.00
Total :